During the study, participants will be assigned to receive either the new experimental drug EL219 or the standard medications. To ensure the results are unbiased, a double-blind method is used, meaning neither the patients nor the medical staff know which specific treatment is being administered. In this process, some participants may receive a placebo, which is an inactive substance used for comparison. The course of the study involves monitoring the participants over a period of time to see how they respond to the treatments and to track any side effects.

The purpose of this research is to evaluate how well fosmanogepix works and how safe it is for treating adults who have serious fungal infections. The study will look at whether the treatment helps patients survive and recover from their infections. The treatment period can last up to 180 days, depending on how each patient responds.

During the study, doctors will monitor patients’ progress through various tests and examinations. They will check how well the infection responds to treatment by looking at clinical symptoms, laboratory tests, and imaging scans. They will also carefully track any side effects that may occur during treatment.

Participants in the study will receive fluconazole in different forms, including capsules, oral suspension, or as a solution for infusion. The study will observe how the body processes the medication, which is known as pharmacokinetics. This includes understanding how fluconazole is absorbed, distributed, and cleared from the body. The goal is to ensure that the medication is used effectively and safely in young patients.

The study will take place over a period of time, with participants receiving fluconazole either as a preventive measure or as a treatment for their fungal infections. The researchers will collect data to help improve the dosing guidelines for fluconazole in children and adolescents, ensuring that the medication is both effective and safe for this age group. The study will also explore factors that might affect how the medication works, such as body weight and kidney function.

The medication being tested, caspofungin (brand name Cancidas), is available in two different strengths: 50 mg and 70 mg. It comes as a powder that is mixed with sodium chloride solution to create a liquid that can be given through a vein. The treatment period lasts for up to 8 weeks, during which patients receive daily doses of either caspofungin or placebo.

During the study, doctors will monitor patients for 28 days after starting treatment to see how well the medication works. They will also track patients’ progress for up to 90 days to gather additional information about the treatment’s effectiveness and safety. The study uses a double-blind design, which means neither the patients nor their doctors know who is receiving caspofungin or placebo during the treatment period.

The main goal of the study is to determine if using Fluconazole as a preventive treatment can help reduce the number of complications that occur after a cystectomy. Participants in the study will receive either Fluconazole or a placebo during their treatment. The study will monitor various outcomes, such as the number of days participants are alive and out of the hospital within 90 days after surgery, the time it takes for their digestive system to start working again, and their overall quality of life. The study will also look at the length of hospital stay, the need for re-admission, and any infections that require treatment.

Throughout the study, participants will be closely monitored to ensure their safety and to gather information on how well the treatment works. The trial is expected to continue until the end of 2026, with recruitment starting in early 2024. This research aims to provide valuable insights into improving recovery and reducing complications for patients undergoing cystectomy.

The study will involve children who are suspected or confirmed to have an invasive fungal infection. Participants will receive Posaconazole either as an oral suspension or through an intravenous infusion. The study will monitor how the medication is absorbed and processed in the body, as well as its safety and any side effects. The study is divided into different panels, with some children receiving a single dose and others receiving multiple doses over a period of time.

Throughout the study, researchers will collect information on how the medication affects the children, including any adverse events or side effects. The study aims to provide valuable information on the use of Posaconazole in very young children, which could help improve treatment options for those with serious fungal infections. The study is expected to continue until 2025, allowing researchers to gather comprehensive data on the medication’s effects in this age group.

Participants in the study will be randomly assigned to receive either Olorofim or AmBisome followed by standard care. The study will last for a period of up to 91 days, during which the health and progress of the participants will be closely monitored. The study will assess various outcomes, including the overall response to the treatment and the survival rate of the participants. The study will also look at the quality of life of the participants during and after the treatment period.

This trial is designed to provide valuable information on the best treatment options for patients suffering from invasive aspergillosis. By comparing the two treatments, researchers hope to find the most effective way to manage this serious infection and improve patient outcomes. Participants will be under the care of medical professionals throughout the study to ensure their safety and well-being.

The study will involve giving a single dose of Rezafungin Acetate to participants and monitoring them to see how the medication is absorbed, distributed, and eliminated by the body. Researchers will also keep a close eye on any side effects or changes in health that might occur during the study. This will help determine if the medication is safe and effective for use in children with fungal infections.

Throughout the study, participants will undergo various health checks, including blood tests and heart monitoring, to ensure their safety. The information gathered from this trial will contribute to understanding the potential benefits and risks of using Rezafungin Acetate in young patients with fungal infections.

The purpose of the study is to determine if posaconazole is more effective than fluconazole in reducing the risk of invasive mold infections, which are a type of fungal infection. Participants in the study will be randomly assigned to receive either posaconazole or fluconazole as a preventive measure. Some participants may receive a placebo, which is a substance with no active medication. The treatment period will last up to 180 days, during which the occurrence of fungal infections will be monitored.

Throughout the study, participants will be closely observed for any side effects or adverse reactions to the medications. The study aims to provide valuable information on the best approach to prevent fungal infections in patients with acute myeloid leukemia, ultimately improving their treatment outcomes and quality of life. The trial is expected to conclude by the end of 2025.